Report Overview

United States Sexually Transmitted Disease (STD) Testing Market - Industry Trends & Forecast Report, 2029

United States sexually transmitted disease (STD) testing market size was estimated at USD 3.62 billion in 2022. During the forecast period between 2023 and 2029, the size of United States sexually transmitted disease (STD) testing market is projected to grow at a CAGR of 8.6% reaching a value of USD 6.47 billion by 2029. Major growth drivers for the United States sexually transmitted disease (STD) testing market include increasing awareness, changing sexual behaviors, and growing instances of sexually transmitted infections (STIs) among young adults. On March 16 , 2023, the CDC released preliminary data that underscores the resurgence of STDs in the second year of the pandemic. In 2021, the U.S. recorded 2.5 million STD cases, marking a 4.4% increase in combined cases of chlamydia, gonorrhea, syphilis, and congenital syphilis. Notably, there was a 49% surge in syphilis cases among women in 2021, and instances of congenital syphilis increased by 24% compared to 2020. These statistics highlight the concerning trend in the prevalence of STDs in the United States. Notably, while this transmission typically occurs through vaginal, oral, or anal contact, it can also result from other intimate physical engagements, including contact with the epidermis, which may transmit diseases like herpes or HPV. These illnesses are caused by bacteria, pathogens, or parasites. In specific instances, STDs can also be passed through breastfeeding, childbirth, and needle-sharing. Advances in diagnostic technology and treatment plans are propelling market growth. Also, the market is expected to continue expanding during the forecast period, owing to education programs and government initiatives. This growth is driven by the increasing adoption of point-of-care testing and technologically sophisticated products, further boosting demand.

United States Sexually Transmitted Disease (STD) Testing Market – Overview

The United States sexually transmitted disease (STD) testing market refers to the sector of the healthcare industry in the United States focused on the testing, diagnosis, and screening of individuals for sexually transmitted disease (STD)s. This market encompasses a wide range of testing methods, diagnostic tools, and services aimed at identifying and monitoring the presence of various STDs, including but not limited to chlamydia, gonorrhea, syphilis, HIV, herpes, and HPV. It involves both public and private healthcare providers, laboratories, and facilities that offer STD testing services, and it is influenced by factors such as awareness, government initiatives, technological advancements, and changes in sexual behavior. The market seeks to address the prevention, early detection, and treatment of STDs to mitigate their impact on public health.

United States Sexually Transmitted Disease (STD) Testing Market

Growth Drivers

Increasing Prevalence of STDs

The rising prevalence of STDs is expected to drive the demand for STD testing kits and tools, particularly in developing nations. Other contributing factors, such as sharing sexual accessories and a lack of emphasis on safe sexual practices, as well as needle-sharing for drug or steroid use, are increasing the risk of STD transmission. Limited provider knowledge and counseling skills are resulting in a growing population of undiagnosed individuals with STDs worldwide. Also, a significant portion of the population is hesitant to get tested due to perceived stigma and confidentiality concerns associated with STIs.

Restraints

Cost of Testing

The cost of testing serves as a significant restraint on the growth of the United States sexually transmitted disease (STD) testing market. While STD testing is crucial for public health, the expenses associated with diagnostic procedures, especially for individuals without comprehensive health insurance coverage, can act as a deterrent. This financial barrier may discourage many at-risk individuals from seeking regular testing or treatment, potentially contributing to the spread of STDs. Efforts to expand affordable testing options, promote insurance coverage, and increase access to low-cost or free testing services are essential to mitigate this challenge and address the economic barrier hindering market growth.

Impact of COVID-19 on United States Sexually Transmitted Disease (STD) Testing Market

COVID-19 pandemic adversely affected the United States sexually transmitted disease (STD) testing market. This impact was mainly due to a reduction in STD testing rates, leading to a substantial increase in unreported cases and the potential for heightened disease transmission. In fiscal year 2020, prominent market players faced challenges, witnessing a decline in their segmental revenue growth, primarily as a consequence of the novel COVID-19 pandemic. The combination of reduced testing and the broader economic repercussions of the pandemic underscored the vulnerability of the STD testing market during times of public health crises.

United States Sexually Transmitted Disease (STD) Testing Market

Segmental Coverage

United States Sexually Transmitted Disease (STD) Testing Market – By Disease Type

Based on disease type, the United States sexually transmitted disease (STD) testing market is divided into Chlamydia, Gonorrhea, Genital Herpes, Syphilis, Human Immunodeficiency Virus, and Human papillomavirus (HPV) segments. The chlamydia segment holds the highest share in the United States sexually transmitted disease (STD) market during the forecast period by disease type. Chlamydia is one of the most common STDs in the country, contributing to its significant prevalence. Routine screening programs and awareness campaigns have also driven increased testing for chlamydia. Additionally, the disease is often asymptomatic, making regular testing vital for early detection. With its relatively high incidence and the focus on prevention and early diagnosis, the chlamydia segment is poised to maintain its leading position during the forecast period in the United States STD market.

United States Sexually Transmitted Disease (STD) Testing Market – By Product Type

Based on product type, the United States sexually transmitted disease (STD) testing market is split into Instruments and Reagents & Kits segments. The reagents & kits segment is expected to hold a higher share in the United States sexually transmitted disease (STD) testing market during the forecast period by product type. It is primarily due to their fundamental role in conducting STD tests and their widespread use in various testing methods. The convenience and accessibility of at-home STD testing kits, along with the impact of the COVID-19 pandemic, have contributed to the growth of this segment in the market.

United States Sexually Transmitted Disease (STD) Testing Market – By Device Type

Based on device type, the United States sexually transmitted disease (STD) testing (STD) market is bifurcated into Laboratory Devices and Point of care (POC) Devices segments. The laboratory devices segment held a higher share in the United States sexually transmitted disease (STD) testing market by device type. These devices are typically found in clinical laboratories and healthcare facilities, making them essential for conducting a wide range of STD tests accurately and efficiently. They offer the capacity for high-throughput testing, making them suitable for large-scale screening programs and testing campaigns. Moreover, these laboratory devices often provide precise and reliable results, contributing to their preference among healthcare professionals. The stringent quality control and standardized procedures associated with laboratory testing further enhance their trustworthiness, solidifying their dominant position in the United States STD testing market.

United States Sexually Transmitted Disease (STD) Testing Market – By End User

On the basis of end user, the United States sexually transmitted disease (STD) testing market is split into Hospital & Clinics and Clinical Laboratories segments.

Competitive Landscape

Major players operating in the United States sexually transmitted disease (STD) Testing Market include Abbott, bioMerieux Inc., Bio Rad Laboratories Inc., DiaSorin S.p.A, Cepheid (Danaher), Hologic, Inc., F. Hoffmann-La Roche Ltd, BD, and Thermo Fisher Scientific Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

• In July 2023 - Aptitude Medical Systems partnered with the Bill and Melinda Gates Foundation (BMGF) to develop an all-in-one home rapid sexually transmitted infection (STI) test. This point-of-care test, based on the company's COVID-19 testing platform, aims to detect Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. As STI rates rise, this initiative seeks to provide a convenient and accessible solution for testing common STIs, including those with high prevalence like chlamydia and gonorrhea. The Bill & Melinda Gates Foundation's funding supports Aptitude's mission to enhance global health equity through innovative diagnostics.

• In February 2023 - Maternova announced a partnership with MedMira to expand its product offerings, including the Multiplo TP/HIV rapid test and the Reveal G4 HIV rapid test. These tests provide immediate, highly sensitive, and specific results, supporting maternal and infant health by reducing the risk of syphilis and HIV transmission from mother to child. Maternova, a global health solutions company, aims to distribute these quality tests through its network in Latin America and the United States, enhancing healthcare settings. The partnership leverages MedMira's diagnostic technologies and Maternova's commercialization expertise to benefit a broader range of healthcare providers and patients. Maternova also sponsors the Action on Disaster Relief 2023 event, showcasing these products.

• In February 2023 - Biosynex, a France-based rapid test specialist, acquired Chembio Diagnostics, a leading US point-of-care diagnostics company, in an all-cash deal worth USD 17.2 million, representing a 27% premium over Chembio's closing stock price on January 30, 2023. This merger brought together two prominent diagnostic test companies, enabling them to expand their product offerings and create significant cost savings through synergies. Biosynex aimed to strengthen its position as a key player in the European professional point-of-care and self-test diagnostics market, while Chembio anticipated financial stability and enhanced innovation by becoming part of Biosynex.

Scope of the Report

By Disease Type

• Chlamydia

• Gonorrhea

• Genital Herpes

• Syphilis

• Human Immunodeficiency Virus (HIV)

• Human papillomavirus (HPV)

By Product Type

• Instruments

• Reagents & Kits

By Device Type

• Laboratory Devices

• Point of care (PoC) Devices

By End User

• Hospital & Clinics

• Clinical Laboratories

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Executive Summary
3. United States Sexually Transmitted Disease (STD) Testing Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
         1. Increasing prevalence of STDs
         2. Increasing awareness of STDs and the importance of testing
      2. Restraints
         1. Cost of testing
         2. Stigma associated with STDs
      3. Opportunities
         1. Development of new STD testing technologies
         2. Expansion of telemedicine
      4. Challenges
         1. Regulatory compliance
         2. Privacy concerns
   3. Technological Advancements/Recent Developments
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
4. United States Sexually Transmitted Disease (STD) Testing Market Overview
   1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Disease Type
         1. Chlamydia
         2. Gonorrhea
         3. Genital Herpes
         4. Syphilis
         5. Human Immunodeficiency Virus (HIV)
         6. Human papillomavirus (HPV)
         7. Others
      2. By Product Type
         1. Instruments
         2. Reagents & Kits
      3. By Device Type
         1. Laboratory Devices
         2. Point of care (PoC) Devices
      4. By End-User
         1.  Hospital & Clinics
         2. Clinical Laboratories
         3. Others
5. Competitive Landscape
   1. List of Key Players and Their Range
   2. United States Sexually Transmitted Disease (STD) Testing Company Market Share Analysis, 2022
   3. Competitive Benchmarking, By Operating Parameters
   4. Key Strategic Development (Merger, Acquisition, Partnership)
6. Impact of Covid-19 on United States Sexually Transmitted Disease (STD) Testing Market Industry
7. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook, SWOT Analysis)
   1. Abbott
   2. bioMerieux Inc.
   3. Bio Rad Laboratories Inc.
   4. DiaSorin S.p.A
   5. Cepheid (Danaher)
   6. Hologic, Inc.
   7. F. Hoffmann-La Roche Ltd
   8. BD
   9. Thermo Fisher Scientific Inc.
   10. Other prominent players
8. Key Strategic Recommendations
9. Research Methodology
   1. Qualitative Research
      1. Primary & Secondary Research
   2. Quantitative Research
   3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
   4. Breakdown of Primary Research Respondents
   5. Assumption & Limitation

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.

List of Figures

Figure 1       United States Sexually Transmitted Disease (STD) Testing Market Segmentation

Figure 2       United States Sexually Transmitted Disease (STD) Testing Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2021

Figure 4       United States Sexually Transmitted Disease (STD) Testing Market Size, By Value (USD Million), 2019–2029

Figure 5       United States Sexually Transmitted Disease (STD) Testing Market Share, By Disease Type, By Value, 2019–2029

Figure 6       United States Sexually Transmitted Disease (STD) Testing Market Share, By Product Type, By Value, 2019–2029

Figure 7       United States Sexually Transmitted Disease (STD) Testing Market Share, By Device Type, By Value, 2019–2029

Figure 8       United States Sexually Transmitted Disease (STD) Testing Market Share, By End-User, By Value, 2019–2029

List of Tables      

Table 1        United States Sexually Transmitted Disease (STD) Testing Market Share, By Disease Type, By Value, 2019–2029

Table 2        United States Sexually Transmitted Disease (STD) Testing Market Share, By Product Type, By Value, 2019–2029

Table 3        United States Sexually Transmitted Disease (STD) Testing Market Share, By Device Type, By Value, 2019–2029

Table 4        United States Sexually Transmitted Disease (STD) Testing Market Share, By End-User, By Value, 2019–2029

Table 5        Abbott Company Overview

Table 6        Abbott Financial Overview

Table 7        bioMerieux Inc. Company Overview

Table 8        bioMerieux Inc. Financial Overview

Table 9        Bio Rad Laboratories Inc. Company Overview

Table 10      Bio Rad Laboratories Inc. Financial Overview

Table 11      DiaSorin S.p.A Company Overview

Table 12      DiaSorin S.p.A Financial Overview

Table 13      Cepheid (Danaher) Company Overview

Table 14      Cepheid (Danaher) Financial Overview

Table 15      Hologic, Inc. Company Overview

Table 16      Hologic, Inc. Financial Overview

Table 17      F. Hoffmann-La Roche Ltd Company Overview

Table 18      F. Hoffmann-La Roche Ltd Financial Overview

Table 19      BD Company Overview

Table 20      BD Financial Overview

Table 21      Thermo Fisher Scientific Inc. Company Overview

Table 22      Thermo Fisher Scientific Inc. Financial Overview